Değer202020212022202320242025TTMSatış/genel/idari giderler9.8 M10.86 M10.32 M9.73 M9.44 M8.89 M—Araştırma ve geliştirme22.76 M28.69 M30.65 M34.47 M24.81 M22.76 M—Faaliyet karı-31.5 M-35.07 M-35.37 M-12.99 M-14.89 M31.33 M—Faaliyet Dışı Gelir, Toplam1.83 M893 K1.78 M3.25 M5.22 M4.1 M—Faiz gideri (aktifleştirilmiş faizler düşüldükten sonra)———————Faaliyet Dışı Gelir (Faiz Giderleri Hariç)1.83 M893 K1.78 M3.25 M5.22 M4.1 M—Olağandışı gelirler/giderler———————Vergi öncesi kar-29.7 M-34.2 M-33.64 M-9.78 M-9.71 M35.4 M-17.73 MKazançlardaki özsermayeler———————Vergiler0058 K8.97 M4.52 M54 K—Kontrol gücü olmayan/azınlık payı———————Vergi sonrası diğer gelirler/giderler———————Durdurulan faaliyetler öncesi net kar-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MDurdurulan faaliyetler———————Net kar-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MSeyreltme ayarlaması———————İmtiyazlı temettüler———————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MTemel hisse başına kazanç (Temel EPS)-0.37-0.41-0.39-0.21-0.160.38—Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)-0.37-0.41-0.39-0.21-0.160.38-0.23Dolaşımdaki ortalama adi hisse senedi sayısı79.59 M84.2 M86.56 M87.63 M89.53 M93.43 M—Dolaşımdaki seyreltilmiş hisse senedi sayısı79.59 M84.2 M86.56 M87.63 M89.53 M93.82 M—FAVÖK-29.95 M-33.32 M-28.87 M-12.19 M-14.4 M31.8 M—FVÖK-31.5 M-35.07 M-35.37 M-12.99 M-14.89 M31.33 M—Gelir maliyeti60 K680 K975 K2 M7.93 M9.25 M—Satılan malların diğer maliyeti———————Amortisman ve itfa (nakit akışı)1.54 M1.75 M6.5 M801 K486 K475 K—
Compugen Ltd. - Ordinary Shares
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.